Core Insights - The 2025 Very Food Annual "Gut Health Award" was awarded to Microbiome Probiotics' BLa80 strain, highlighting its exceptional gut health benefits and solid scientific evidence [1][2] - BLa80, derived from healthy breast milk samples in the Sichuan plateau, marks a significant breakthrough for China in the infant probiotic sector, being officially recognized by the National Health Commission [2] - The successful development of BLa80 reflects China's transition from following to competing and eventually leading in the probiotic industry [2] Company Achievements - The development of BLa80 involved over ten years of research by the Microbiome team, including comprehensive genomic analysis and rigorous clinical studies [4] - More than 20 clinical studies have been conducted on BLa80, involving over 2,500 participants, including 1,100 infants, demonstrating its safety and efficacy in improving infant health [4] - BLa80 has shown significant effects in reducing infant diarrhea, lowering allergy incidence, alleviating eczema, and enhancing immune function [4] Research and Development - Microbiome Probiotics has established a robust evidence-based research system, conducting over 100 clinical studies across six health domains, including metabolic and immune health [8] - The company has built four state-of-the-art probiotic manufacturing plants in China, covering a total area of 100,000 square meters, ensuring a stable production capacity of over 1,000 tons of high-activity probiotic powder annually [8] Industry Outlook - The global probiotic industry is entering a critical phase focused on scientific evidence, quality, and industrialization [10] - Experts predict that the industry will evolve towards more precise, efficient, and personalized probiotic solutions [10] - Microbiome Probiotics aims to contribute to national health by continuing to develop scientifically validated probiotic strains, enhancing China's presence in the global probiotic research arena [10]

Core Viewpoint - The 2025 Microbiome International Probiotic and Health Summit, co-hosted by Weikang Probiotics and the APC Microbiome Centre of Ireland, emphasizes the theme "Quality Bacteria, Quality Life," focusing on the forefront of probiotic research, evidence-based innovation, and sustainable development strategies in the industry [1][8]. Group 1: Keynote Addresses - Dr. Fang Shuguang, Chairman and Chief Scientist of Weikang Probiotics, and Paul Ross, a member of the American Academy of Microbiology and the Royal Irish Academy, delivered keynote addresses at the summit [5][9]. - The summit highlighted the transition of the global probiotic industry towards a science-based, quality-focused, and industrialized era, advocating for rigorous research design and traceable data for quality control [8][11]. Group 2: Research Reports - Renowned scholars, including Catherine Stanton from the Royal Irish Academy and experts from Fudan University and Suzhou University, presented reports on core topics such as cutting-edge probiotic research, scientific evidence, and future development [13]. - Catherine Stanton discussed the establishment of infant gut microbiota and its impact on host health, emphasizing the role of various factors in gut diversity and the clinical benefits of specific probiotics [14][16]. - Other presentations included innovative approaches to gut health management, the necessity of clinical evidence for probiotics, and the potential of probiotics in cancer treatment and chronic disease management [18][20][22][27]. Group 3: Industry Collaboration and Future Directions - The summit served as a vibrant platform for intellectual exchange, fostering meaningful collaborations and innovations in the probiotic field [11]. - Weikang Probiotics is committed to its mission of "Quality Bacteria, Quality Life," focusing on probiotic strain research, clinical evidence, and large-scale production to provide high-quality probiotic solutions for global consumers [27].